PMID: 16528910Mar 15, 2006Paper

Absolute quantitation of cancer-related proteins using an MS-based peptide chip

BioTechniques
Erin N WarrenChristoph H Borchers

Abstract

New technologies are needed that can diagnose cancer more rapidly and accurately. These technologies must also have the ability to identify the particular cellular abnormalities contributing to the malignancy, thus directing the appropriate treatments. Such technologies should permit absolute quantitation of specific tumor biomarkers and their level of posttranslational modifications. Quantitative molecular profiling of cancer signaling networks would provide a more detailed understanding of the contribution of protein expression and posttranslational modification levels to tumorigenesis. We have developed a unique approach for absolute quantitation of protein expression that integrates affinity capture of proteolytic peptides with mass spectrometry and thus provides detection, identification, and quantitation of their cognate proteins. We have previously shown the high sensitivity and specificity of this approach. Here we demonstrate the absolute quantitation of a model peptide using our technology. We have used this approach to capture epitope-containing peptides from proteolytically digested target proteins, including p53, epidermal growth factor receptor (EGFR), and prostate-specific antigen (PSA). Our technology can easily...Continue Reading

References

Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·D SuckauM Przybylski
Jan 1, 1990·Methods in Enzymology·K Biemann
Nov 1, 1984·Biomedical Mass Spectrometry·P Roepstorff, J Fohlman
Feb 28, 2002·Lancet·Emanuel F PetricoinLance A Liotta
Mar 6, 2002·Molecular Biotechnology·Carol E Parker, Kenneth B Tomer
Feb 26, 2003·Proteomics·Elaine ScrivenerJonathan Terrett
Mar 14, 2003·Nature·Ruedi Aebersold, Matthias Mann
May 29, 2003·Proceedings of the National Academy of Sciences of the United States of America·Scott A GerberSteven P Gygi
Jul 15, 2003·Nature Biotechnology·Jeroen KrijgsveldAlbert J R Heck
Apr 1, 1995·Analytical Chemistry·R W NelsonP Williams
Jun 22, 2005·Expert Review of Proteomics·Mark Brönstrup

❮ Previous
Next ❯

Citations

Mar 5, 2010·Journal of the American Society for Mass Spectrometry·Jennifer D ReidChristoph H Borchers
Nov 14, 2015·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Tove BoströmSophia Hober
Sep 1, 2018·Expert Review of Proteomics·Robert PoppChristoph Borchers
Dec 1, 2007·Proteomics. Clinical Applications·Jian JiangChristoph H Borchers
Mar 20, 2020·International Journal of Molecular Sciences·Ghaith M HamzaJeffrey C Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.